Key facts
- It has raised $366.1M across 4 recorded rounds; the latest was Later Stage VC ($118.5M) in Mar 2023.
- Notable investors include Korea Investment Partners, Gates Foundation, Salica Investments, Johnson & Johnson Innovation - JLABS, Shinhan Capital — 38 tracked in total.
- Vedanta Biosciences has filed 7 Form Ds with the SEC since 2019, most recently Aug 2024 ($118.5M sold to 25 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 38 names
- ·Watchlist + deal alerts for Vedanta Biosciences
Funding rounds
4 roundsAbout Vedanta Biosciences
Developer of orally delivered defined bacterial consortia designed to treat inflammatory and infectious diseases. The company's platform includes libraries of bacteria derived from the human microbiome, vast datasets from human interventional studies, proprietary capabilities in consortium design, and CGMP manufacturing through commercial launch, leading to the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks, enabling physicians to access oral therapies to treat autoimmune and inflammatory diseases efficiently.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2010
- Employees
- 136
- Website
- vedantabio.com/
- Ownership
- Privately Held (backing)
Vedanta Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vedanta Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vedanta Biosciences in its N-PORT filings yet. We sweep new filings monthly.